Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs
Amgad M. Rabie
Abstract
<bold>CoViTris2020</bold> and <bold>ChloViD2020</bold> inhibit SARS-CoV-2 life cycle with EC<sub>50</sub> values of 0.31 and 1.01 μM, respectively. <bold>CoViTris2020</bold> strongly inhibits coronaviral-2 RdRp with lower inhibitory binding energy of −12.00 kcal mol<sup>−1</sup>.
Topics & Concepts
ChemistryRepurposingCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakDrug repositioningPharmacologyAntioxidantVirologyDrugBiochemistryInternal medicineBiologyEcologyOutbreakMedicineDiseaseInfectious disease (medical specialty)Computational Drug Discovery MethodsMosquito-borne diseases and controlCOVID-19 Clinical Research Studies